JPRN-jRCT2071230094CompletedUnknown
Trastuzumab BS 60mg,150mg NK for intravenous infusion. Long-term specific use results survey targeting gastric cancer patients with confirmed HER2 overexpression. - /
/ / /0 sites150 target enrollmentStarted: November 22, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •HER2 positive gastric cancer
Exclusion Criteria
- •Not set: The following is set as a precaution when selecting patients.
Investigators
Similar Trials
Completed
Not Applicable
Safety and Efficacy of Trastuzumab BSGastric CancerNCT04181333Pfizer8
Completed
Not Applicable
Feasibility study of a short Trastuzumab infusion in patients with breast cancer.breast cancerJPRN-UMIN000018294IPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITA20
Completed
Phase 2
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
Completed
Phase 2
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells10006232<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18
Active, not recruiting
Not Applicable
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous hromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active-Controlled Open Label StudyMedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisVenous thrombolic eventsEUCTR2008-004539-39-LVThromboGenics N.V300